Portuguese Polyneuritic Amyloidosis

Definition:

Portuguese Polyneuritic Amyloidosis, also known as Familial Amyloid Polyneuropathy (FAP), is a hereditary autonomic and peripheral polyneuropathy caused by the accumulation of amyloid fibrils in the nervous system, leading to severe neurological dysfunction.

Subtypes of Portuguese Polyneuritic Amyloidosis:

There are three major subtypes of Portuguese Polyneuritic Amyloidosis:

  1. FAP-Type I:

    Also known as “Andrade type” or “early-onset type,” FAP-Type I manifests before the age of 30 and primarily affects peripheral nerves. Symptoms may include sensory and motor disturbances, autonomic dysfunction, gastrointestinal problems, and cardiac abnormalities.

  2. FAP-Type II:

    Also referred to as “Póvoa de Varzim type” or “late-onset type,” FAP-Type II typically occurs after the age of 30 and involves both peripheral and autonomic neuropathy. Initial symptoms mainly appear in the lower limbs and progress upwards. Affected individuals may experience sensory loss, muscle weakness, digestive complications, and cardiovascular issues.

  3. FAP-Type III:

    Known as “van Allen type” or “exclusive cardiac neuropathy,” FAP-Type III primarily affects the heart, leading to cardiomyopathy and conduction abnormalities. Neurological symptoms are absent or minimal, focusing on the cardiac system.

Cause and Genetic Mutation:

Portuguese Polyneuritic Amyloidosis is primarily caused by a genetic mutation in the transthyretin (TTR) gene, leading to the deposition of mutated amyloid fibrils in various tissues, including the peripheral nerves. This mutation is inherited in an autosomal dominant manner.

Clinical Features:

The clinical presentation of Portuguese Polyneuritic Amyloidosis encompasses a range of symptoms related to peripheral and autonomic neuropathy. These may include:

  • Sensory disturbances, such as numbness, tingling, and pain
  • Motor deficits, including muscle weakness and loss of coordination
  • Orthostatic hypotension and other autonomic dysfunctions
  • Gastrointestinal problems, such as diarrhea, constipation, and difficulty swallowing
  • Cardiovascular complications, including arrhythmias, cardiomyopathy, and heart failure

Diagnosis:

The diagnosis of Portuguese Polyneuritic Amyloidosis involves a combination of clinical evaluation, genetic testing to detect TTR gene mutations, imaging studies (e.g., nerve conduction studies, electromyography), tissue biopsy to identify amyloid deposits, and specialized tests, such as cardiac evaluations and autonomic function assessments.

Treatment:

Currently, treatment options for Portuguese Polyneuritic Amyloidosis focus on symptom management, slowing disease progression, and improving quality of life. These may include:

  • Medications to stabilize or reduce amyloid fibril formation
  • Pain management strategies
  • Supportive therapies to address autonomic dysfunction and gastrointestinal symptoms
  • Adequate nutrition and physical therapy

Prognosis:

The prognosis for individuals with Portuguese Polyneuritic Amyloidosis varies depending on the subtype and severity of the disease. Without treatment, the condition typically progresses, leading to significant disability and decreased life expectancy. However, advances in treatment options and supportive care have improved outcomes for many affected individuals.